Side by side · Updated April 2026

Ozempic vs. Rybelsus

Both are GLP-1 receptor agonists. Beyond that they differ in molecule, FDA indication, dose ceiling, and — most importantly to most people reading this — what the scale actually does over the long run.

Semaglutide vs Semaglutide (oral)Type 2 diabetes… vs. Type 2 diabetes…

Semaglutide

Ozempic

GLP-1

Made by: Novo Nordisk
FDA approval: December 2017
Indication: Type 2 diabetes (with later cardiovascular and CKD indications)
Dose ceiling: 2.0 mg weekly
Typical loss: ~6% body weight at 6–12 months in T2D patients; ~10–13% in non-diabetic off-label use at higher doses
Cash list: $950–$1,350

Semaglutide (oral)

Rybelsus

GLP-1

Made by: Novo Nordisk
FDA approval: September 2019
Indication: Type 2 diabetes
Dose ceiling: 14 mg daily (25 mg and 50 mg under FDA review for obesity in 2025)
Typical loss: ~3–4% body weight at 6 months in T2D; OASIS-1 trial of oral semaglutide 50 mg showed ~15% weight loss at 68 weeks (not yet approved for obesity as of early 2026)
Cash list: $950–$1,150 list

The honest answer

Which one actually wins

Same molecule (semaglutide), different delivery. Ozempic is once-weekly injection. Rybelsus is daily oral with a 30-minute empty-stomach ritual. Ozempic produces meaningfully more weight loss at maximum dose because the oral bioavailability is so low (~1%). Rybelsus is mostly chosen by needle-averse patients and those who already follow a structured morning routine.

Side by side

Ozempic vs Rybelsus, ten metrics

MetricOzempicRybelsus

Molecule

OzempicSemaglutide

RybelsusSemaglutide (oral)

Receptor(s)

OzempicGLP-1

RybelsusGLP-1

Manufacturer

OzempicNovo Nordisk

RybelsusNovo Nordisk

FDA approval

OzempicDecember 2017

RybelsusSeptember 2019

Indication

OzempicType 2 diabetes (with later cardiovascular and CKD indications)

RybelsusType 2 diabetes

Delivery

OzempicSubcutaneous injection, once weekly

RybelsusOral tablet, once daily

Dose ceiling

Ozempic2.0 mg weekly

Rybelsus14 mg daily (25 mg and 50 mg under FDA review for obesity in 2025)

Titration

Ozempic4 weeks per step

Rybelsus30 days per step

Typical loss

Ozempic~6% body weight at 6–12 months in T2D patients; ~10–13% in non-diabetic off-label use at higher doses

Rybelsus~3–4% body weight at 6 months in T2D; OASIS-1 trial of oral semaglutide 50 mg showed ~15% weight loss at 68 weeks (not yet approved for obesity as of early 2026)

Cash list

Ozempic$950–$1,350

Rybelsus$950–$1,150 list

On patent until

Ozempic2031 (US composition of matter)

Rybelsus2031 (with formulation patents extending further)

Where to get it